ANLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Adlai Nortye Group Ltd.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 10, 2026
$10.38−0.65 (-5.89%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2020 to 2025
Operating margin
-714.0%
Net margin
-710.6%
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
6 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2020 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on assets | – | – | -67.2% | |
| Current ratio | – | – | 0.65 | |
| Interest coverage | – | – | -23.3× | |
| Capex to revenue | – | – | 3.7% | |
| Diluted shares | – | – | 96M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Adlai Nortye generated $188.18M from operations and spent $2.82M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$188.18M
Used
$2.82M
Capital expenditure$2.82M100%Dividends$00%Share buybacks$00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$35.53M
- Cash generatingOperating cash flow above zero-$33.45M
- Return on assets improvedROA up on the prior year-39.8% → -49.8%
- Earnings backed by cashOperating cash flow above net income-$33.45M vs -$35.53M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose1.41 → 0.65
- No dilutionShare count did not rise96M → 96M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → 0.07